A comprehensive approach to Parkinson's disease

Postgraduate Medicine

Volumn 119, Issue 1, 2006, Pages

  Brunton, Stephen ^a,b,c  

^a GLAXOSMITHKLINE   (United States)

^b Cabarrus/Northeast Medical Center   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; SELEGILINE;

AUTOPSY; CLINICAL ASSESSMENT; CLINICAL FEATURE; DEGENERATIVE DISEASE; DOCTOR PATIENT RELATION; DRUG COST; DRUG HALF LIFE; DYSKINESIA; GENE MUTATION; HUMAN; MUSCLE RIGIDITY; PARKINSON DISEASE; PATIENT CARE; PHYSICIAN; PRIMARY HEALTH CARE; REVIEW; TREMOR;

EID: 33746480233     PISSN: 00325481     EISSN: 12182583     Source Type: Journal    
DOI: 10.3810/pgm.2006.06.1643     Document Type: Review

References (24)

1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004; 363( 9423): 1783-93
2. Baldereschi M, DiCarlo A, Rocca WA, et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 2000; 55( 9): 1358-63
3. de Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54( 11 Suppl 5): S21-3
4. Schrag A, Ben-Shlomo Y, Quinn NP. Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London. BMJ 2000; 321( 7252): 21-2
5. Priyadarshi A, Khuder SA, Schaub EA, et al. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res 2001; 86( 2): 122-7
6. Checkoway H, Powers K, Smith-Weller T, et al. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 2002; 155( 8): 732-8
7. Litvan I, Bhatia KP, Burn DJ, et al; Movement Disorders Society Scientific Issues Committee. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003; 18( 5): 467-86
8. Harris Interactive. The difficult lives of patients with Parkinson's disease. Health Care News 2003; 3( 15): 1-7
9. Djaldetti R, Shifrin A, Rogowski Z, et al. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology 2004; 62( 12): 2171-5
10. BuzasB, MaxMB. Pain in Parkinson disease. Neurology 2004; 62( 12): 2156-7
11. Sawabini KA, Watts RL. Treatment of depression in Parkinson's disease. Parkinsonism Relat Disord 2004; 10 Suppl 1: S37-41
12. Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002; 359( 9317): 1589-98
13. Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 2004; 61( 1): 97-102
14. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363( 9416): 1179-83
15. Holloway RG, Shoulson I, Fahn S, et al; Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61( 7): 1044-53 [Erratum, Arch Neurol 2005;62(3):430]
16. Swope DM. Rapid treatment of ?wearing off? in Parkinson's disease. Neurology 2004; 62( 6 Suppl 4): S27-31
17. Ives NJ, Stowe RL, Marro J, et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3,525 patients. BMJ 2004; 329( 7466): 593
18. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ 1995; 311( 7020): 1602-7
19. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287( 13): 1653-61
20. Whone AL, Watts RL, Stoessl AJ, et al; REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54( 1): 93-101
21. FahnS, OakesD, ShoulsonI, et al; Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351( 24): 2498-508
22. RektorovaI, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10( 4): 399-406
23. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351( 24): 2509-18
24. Deep-Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001; 345( 13): 956-63